TORONTO, Ontario – June 13, 2022 – The launches of new medicines in Canada declined consistently and markedly in Canada over the past five years as ongoing changes to the pharmaceutical policy environment, including federal medicine pricing reforms (i.e., PMPRB reforms), have caused uncertainty about the Canadian market.
Read MoreBioTalent Canada today announced the kickoff of a $1.15M research study titled Building Resiliency and Sustainability for the Bio-economy to Withstand Disruption. The project, funded by the Future Skills Centre, which wraps up in September 2022, will leverage lessons learned from the pandemic to ensure long-term sustainability within Canada’s bio-economy.
Read MoreOTTAWA, ON, March 16, 2021 /CNW/ - Canadians have demonstrated a remarkable ability to mobilize in response to the COVID–19 pandemic. Companies in the biomanufacturing space from coast to coast to coast have answered the call, and the government wants to recognize their work. To date, the Government of Canada has made investments of approximately $1 billion to advance industrial research and development in vaccines and pharmaceuticals, as well as biomanufacturing capacity. We will continue to partner with Canadian industry and businesses to protect Canadians from COVID-19 while building new biomanufacturing capacity as part of our recovery plan.
Read MoreA letter from BIOQuébec, Montréal InVivo, Life Sciences Ontario and LifeSciences BC, expressing our common vision of the important role of Intellectual Property (IP) protection in our knowledge driven economy.
Read More
